AbCellera Biologics Inc. Net Income (Loss) Available to Common Stockholders, Diluted
AbCellera Biologics Inc. (ABCL) reported Net Income (Loss) Available to Common Stockholders, Diluted of -$55.43 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2026-08-05
- AbCellera Biologics Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2026-06-30 was -$55.43M.
- AbCellera Biologics Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2026-03-31 was -$43.16M.
- AbCellera Biologics Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2025-12-31 was -$8.95M.
- AbCellera Biologics Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2025-09-30 was -$57.12M.
- AbCellera Biologics Inc. net income (loss) available to common stockholders, diluted for fiscal 2025 was -$146.41M.
- AbCellera Biologics Inc. net income (loss) available to common stockholders, diluted for fiscal 2024 was -$162.86M.
- AbCellera Biologics Inc. net income (loss) available to common stockholders, diluted for fiscal 2023 was -$146.40M, a 192.35% decline from fiscal 2022.
- AbCellera Biologics Inc. net income (loss) available to common stockholders, diluted for fiscal 2022 was $158.52M, a 3.29% increase from fiscal 2021.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 6 month | Net Income (Loss) Available to Common Stockholders, Diluted 9 month | Net Income (Loss) Available to Common Stockholders, Diluted 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$55.43M 10-Q · filed 2026-08-05 | -$98.59M 10-Q · filed 2026-08-05 | -$107.54M derived: sum of 3 quarters · filed 2026-08-05 | -$164.66M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$43.16M 10-Q · filed 2026-05-11 | -$52.11M derived: sum of 2 quarters · filed 2026-05-11 | -$109.23M derived: sum of 3 quarters · filed 2026-05-11 | -$143.96M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | -$8.95M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$66.06M derived: sum of 2 quarters · filed 2026-02-24 | -$100.79M derived: sum of 3 quarters · filed 2026-08-05 | -$146.41M 10-K · filed 2026-02-24 |
| 2025-09-30 | -$57.12M 10-Q · filed 2025-11-06 | -$91.85M derived: sum of 2 quarters · filed 2026-08-05 | -$137.47M 10-Q · filed 2025-11-06 | -$171.68M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$34.73M 10-Q · filed 2026-08-05 | -$80.35M 10-Q · filed 2026-08-05 | -$114.56M derived: sum of 3 quarters · filed 2026-08-05 | -$165.66M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$45.62M 10-Q · filed 2026-05-11 | -$79.83M derived: sum of 2 quarters · filed 2026-05-11 | -$130.94M derived: sum of 3 quarters · filed 2026-05-11 | -$167.87M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | -$34.21M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$85.32M derived: sum of 2 quarters · filed 2026-02-24 | -$122.25M derived: sum of 3 quarters · filed 2026-02-24 | -$162.86M 10-K · filed 2026-02-24 |
| 2024-09-30 | -$51.11M 10-Q · filed 2025-11-06 | -$88.04M derived: sum of 2 quarters · filed 2025-11-06 | -$128.65M 10-Q · filed 2025-11-06 | -$175.80M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | -$36.93M 10-Q · filed 2025-08-07 | -$77.54M 10-Q · filed 2025-08-07 | -$124.69M derived: sum of 3 quarters · filed 2026-02-24 | -$153.30M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | -$40.61M 10-Q · filed 2025-05-08 | -$87.76M derived: sum of 2 quarters · filed 2026-02-24 | -$116.37M derived: sum of 3 quarters · filed 2026-02-24 | -$146.90M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | -$47.15M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$75.76M derived: sum of 2 quarters · filed 2026-02-24 | -$106.29M derived: sum of 3 quarters · filed 2026-02-24 | -$146.40M 10-K · filed 2026-02-24 |
| 2023-09-30 | -$28.61M 10-Q · filed 2024-11-04 | -$59.14M derived: sum of 2 quarters · filed 2024-11-04 | -$99.25M 10-Q · filed 2024-11-04 | -$129.14M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | -$30.53M 10-Q · filed 2024-08-06 | -$70.64M 10-Q · filed 2024-08-06 | -$100.53M derived: sum of 3 quarters · filed 2025-02-27 | -$73.91M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | -$40.11M 10-Q · filed 2024-05-07 | -$70.00M derived: sum of 2 quarters · filed 2025-02-27 | -$43.38M derived: sum of 3 quarters · filed 2025-02-27 | -$50.16M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | -$29.89M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$3.27M derived: sum of 2 quarters · filed 2025-02-27 | -$10.05M derived: sum of 3 quarters · filed 2025-02-27 | $158.52M 10-K · filed 2025-02-27 |
| 2022-09-30 | $26.62M 10-Q · filed 2023-11-02 | $19.84M derived: sum of 2 quarters · filed 2023-11-02 | $188.41M 10-Q · filed 2023-11-02 | $248.36M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-06-30 | -$6.79M 10-Q · filed 2023-08-03 | $161.79M 10-Q · filed 2023-08-03 | $221.74M derived: sum of 3 quarters · filed 2024-02-20 | $200.36M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-03-31 | $168.57M 10-Q · filed 2023-05-04 | $228.52M derived: sum of 2 quarters · filed 2024-02-20 | $207.14M derived: sum of 3 quarters · filed 2024-02-20 | $204.82M derived: sum of 4 quarters · filed 2024-02-20 |
| 2021-12-31 | $59.95M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $38.57M derived: sum of 2 quarters · filed 2024-02-20 | $36.24M derived: sum of 3 quarters · filed 2024-02-20 | $153.46M 10-K · filed 2024-02-20 |
| 2021-09-30 | -$21.38M 10-Q · filed 2022-11-08 | -$23.70M derived: sum of 2 quarters · filed 2022-11-08 | $93.52M 10-Q · filed 2022-11-08 | $210.52M derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-06-30 | -$2.32M 10-Q · filed 2022-08-09 | $114.90M 10-Q · filed 2022-08-09 | $231.90M derived: sum of 3 quarters · filed 2023-02-21 | $229.21M derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-03-31 | $117.22M 10-Q · filed 2022-05-10 | $234.22M derived: sum of 2 quarters · filed 2023-02-21 | $231.53M derived: sum of 3 quarters · filed 2023-02-21 | $238.23M derived: sum of 4 quarters · filed 2023-02-21 |
| 2020-12-31 | $117.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-21 | $114.31M derived: sum of 2 quarters · filed 2023-02-21 | $121.01M derived: sum of 3 quarters · filed 2023-02-21 | $118.92M 10-K · filed 2023-02-21 |
| 2020-09-30 | -$2.69M 10-Q · filed 2021-11-10 | $4.01M derived: sum of 2 quarters · filed 2021-11-10 | $1.92M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $6.70M 10-Q · filed 2021-08-13 | $4.61M 10-Q · filed 2021-08-13 | ||
| 2020-03-31 | -$2.09M 10-Q · filed 2021-05-14 | |||
| 2019-12-31 | -$2.21M 10-K · filed 2022-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |